SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ries L,Eisner M,Kosary C, et al. SEER Cancer Statistics Review, 1975–2002, Vol 2006. (based on the November 2004 SEER data submission, posted to the SEER web site 2005) Bethesda, Md: National Cancer Institute, 2005. Available at URL: http://seer.cancer.gov/csr/1975_2002/. Accessed May 1, 2007.
  • 2
    Yancik R,Wesley MN,Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998; 82: 21232134.
  • 3
    Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000; 35: 181200.
  • 4
    Coburn MC,Pricolo VE,Soderberg CH. Factors affecting prognosis and management of carcinoma of the colon and rectum in patients more than eighty years of age. J Am Coll Surg. 1994; 179: 6559.
  • 5
    Hoffman C,Rice D,Sung H. Persons with chronic conditions. Their prevalence and costs. JAMA. 1996; 276: 14731479.
  • 6
    Gill S,Loprinzi CL,Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004; 22: 17971806.
  • 7
    Sundararajan V,Mitra N,Jacobson JS,Grann VR,Heitjan DF,Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002; 136: 349357.
  • 8
    Iwashyna TJ,Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002; 20: 39923998.
  • 9
    Schrag D,Cramer LD,Bach PB,Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001; 93: 850857.
  • 10
    Perrone F,Gallo C,Daniele B. Chemotherapy in the elderly. N Engl J Med. 2002; 346: 622623.
  • 11
    Sargent DJ,Goldberg RM,Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 10911097.
  • 12
    Neugut AI,Fleischauer AT,Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002; 20: 26432650.
  • 13
    Sundararajan V,Grann VR,Jacobson JS,Ahsan H,Neugut AI. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J. 2001; 7: 213218.
  • 14
    Jessup JM,Stewart A,Greene FL,Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005; 294: 27032711.
  • 15
    Potosky A,Riley G,Lubitz J,Mentnech R,Kessler L. Potential for cancer related health services research using a linked Medicare-tumor related database. Med Care. 1993; 31: 732748.
  • 16
    Miller B,Ries L,Hankey B,Kosary C,Edwards B. Cancer Statistics Review 1973–89. NIH Pub. no. 92–2789. Bethesda, Md: National Institutes of Health; 1992.
  • 17
    National Cancer Institute Applied Research Program. Available at URL: http://healthservices.cancer.gov/seermedicare/aboutdata/program.html. Accessed May 1, 2007.
  • 18
    Klabunde CN,Potosky AL,Legler JM,Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 12581267.
  • 19
    Hebert PL,Geiss LS,Tierney EF,Engelgau MM,Yawn BP,McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual. 1999; 14: 270277.
  • 20
    Lamont EB,Lauderdale DS,Schilsky RL,Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002; 40: 201211.
  • 21
    Schrag D,Gelfand SE,Bach PB,Guillem J,Minsky BD,Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results—Medicare. J Clin Oncol. 2001; 19: 37123718.
  • 22
    Dobie SA,Baldwin LM,Dominitz JA,Matthews B,Billingsley K,Barlow W. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006; 98: 610619.
  • 23
    Agency for Healthcare Research and Quality. AHRQ Quality Indicators—Guide to Prevention Quality Indicators: Hospital Admission for Ambulatory Care Sensitive Conditions. AHRQ publication no. 02-R0203, revision 3. Rockville, Md: Agency for Healthcare Research and Quality; 2004.
  • 24
    Andre T,Boni C,Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 23432351.
  • 25
    Du XL,Osborne C,Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002; 20: 46364642.
  • 26
    Potosky AL,Warren JL,Riedel ER,Klabunde CN,Earle CC,Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002; 40(8 suppl ): IV-62IV-68.
  • 27
    Gross CP, Guo Z, McAvay GJ, Allore HG, Young M, Tinetti ME. Multimorbidity and survival among older persons with colorectal cancer. J Am Geriatr Soc. 2006; 54: 18981904.
  • 28
    Allison PD. Missing Data: Sage University Series on Quantitative Applications in the Social Sciences. Thousand Oaks, Calif: Sage Publications; 2002.
  • 29
    Joffe M,Rosenbaum P. Invited commentary: propensity scores. Am J Epidemiol. 1999; 150: 327333.
  • 30
    Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127: 757763.
  • 31
    Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference, Long Beach, Calif, April 22–25, 2001. Cary, NC: SAS Institute, Inc.; paper 21426.
  • 32
    SAS Institute. SAS/STAT 9.1 User's Guide. Cary, NC; 2004.
  • 33
    Becker K,Erckenbrecht JF,Haussinger D,Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999; 57: 475484.
  • 34
    Schober C,Papageorgiou E,Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 1993; 72: 22422247.
  • 35
    Concato J,Shah N,Horwitz R. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000; 342: 18871892.
  • 36
    Benson K,Hartz A. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000; 342: 11781186.
  • 37
    Gross CP,Garg PP,Krumholz HM. The generalizability of observational data to elderly patients was dependent on the research question in a systematic review. J Clin Epidemiol. 2005; 58: 130137.
  • 38
    Cronin DP,Harlan LC,Potosky AL,Clegg LX,Stevens JL,Mooney MM. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006; 101: 23082318.
    Direct Link:
  • 39
    Poon RT,Law WL,Chu KW,Wong J. Emergency resection and primary anastomosis for left-sided obstructing colorectal carcinoma in the elderly. Br J Surg. 1998; 85: 15391542.
  • 40
    Scheithauer W,McKendrick J,Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003; 14: 17351743.
  • 41
    Britton A,McKee M,Black N,McPherson K,Sanderson C,Bain C. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy. 1999; 4: 112121.
  • 42
    Calabresi P,Freeman H. Concerns of special populations. Cancer. 1997; 80: 12581260.
  • 43
    Murthy VH, Li Y, Krumholz HM, Gross CP. Age-, race, and gender-based disparities in cancer trial participation. J Am Med Assoc. 2004; 291: 27202726.
  • 44
    Tunis SR,Stryer DB,Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003; 290(12): 16241632.